FDA drug reviewers said Affymax's peginesatide, a treatment for anemia in dialysis patients with chronic kidney disease, performs comparably with Amgen's Epogen and Aranesp in maintaining an ideal hemoglobin level. However, reviewers voiced concern about peginesatide's safety profile. An FDA panel is set to review the drug Wednesday, and the agency's final decision is anticipated by March 27.

Full Story:

Related Summaries